• Building the Data Foundation for Faster Time to Science in Healthcare

    Nov 23 | Bio-IT World | Genomics and artificial intelligence (AI) are key to this quest and at-scale advancement of personalized medicine. Both, however, require liquid data and modern data infrastructure that re-imagines the role of data and how it is used. More

  • Gut Microbiome Linked To Aggressive Prostate Cancer

    Nov 22 | Bio-IT World | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story. More

  • Biopharma’s Dark Data Problem

    Nov 19 | Bio-IT World | Worldwide spending on pharmaceutical R&D will reach $230 billion by 2026. So with investment dollars flowing in and R&D continuing an upward trajectory all should be well, right? Well… not exactly. Like many industries, pharmaceutical companies are facing a data problem—a dark data problem. More

  • Recursion’s Vision for the New Shape of Drug Discovery

    Nov 17 | Bio-IT World | As a “digital native,” Recursion is working to reshape the drug discovery industry—quite literally. Gone is the vision of a traditional discovery funnel, wide at the top and slowly narrowing. Instead, Recursion proposes a drug discovery machine powering a T-shaped funnel where many options are considered, but failure is fast and the candidates that advance have a potentially higher likelihood of being a successful treatment. Easier said than done. More

  • Unique Repurposing Approach Identifies Potential Alzheimer’s Disease Drug

    Nov 16 | Bio-IT World | Trials for Alzheimer’s disease (AD) drugs have repeatedly failed with billions of dollars invested. But a new, multidisciplinary drug repurposing model, described in a recent article in Nature Aging, combines drug repurposing with precision medicine, network-based drug targeting, induced pluripotent stem cell (iPSC) technology, and real-world data analysis. More

  • MemVerge’s Vision for Big Memory Computing

    Nov 11 | Bio-IT World | The vision, Charles Fan explains, is big memory. Fan and two other co-founders launched MemVerge, an all-memory storage start-up that Fan calls quite disruptive and high risk—but also the compute architecture of the future. More

  • What’s Behind Growing Adoption Of Cell-Based Vaccine Platforms

    Nov 10 | Bio-IT World | Cell-based vaccines, initially developed to add speed and scale to pandemic response efforts and reduce dependency on chickens in the vaccine manufacturing process, have over the past few years also shown to be more reliably effective than traditional, egg-based products. More

  • NVIDIA GTC: Networking, Healthcare AI, Modeling and Simulation

    Nov 09 | Bio-IT World | At the NVIDIA GTC event, wide ranging announcements covered new networking capabilities, new AI capabilities, and new tools to advance healthcare and life sciences research. More

  • Genetic Sequencing Will Enable Us To Win The Global Battle Against COVID-19

    Nov 05 | Bio-IT World | Using genetic sequencing to identify pathogens and respond to outbreaks is hardly new. The emergence of the SARS-CoV-2 in late 2019 was a game-changer, however. While SARS-CoV-2 was identified and sequenced in record time, it proved impossible to contain. It quickly became apparent that existing surveillance systems were not up to the task of tracking a fast-moving virus that spread asymptomatically. The speed and scale of Coronavirus spread provided a wake-up call highlighting our vulnerability to a global pandemic. But bioinformatics plays a crucial role. More

  • ‘Reverse Vaccination’ Has Broad Clinical Potential As Immunotherapy Strategy

    Nov 03 | Bio-IT World | Researchers at the University of Buffalo (UB) have come up with a nanoparticle platform for oral prophylactic immunotherapy designed to pre-expose the immune system to medications it might otherwise perceive as foreign and attack. If translated to the clinic, their novel “reverse vaccination” approach could be used to desensitize patients to key proteins in drug treatments for rare conditions, autoimmune diseases, and allergies. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight

Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!